Polypid, Ltd.
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Institute, hospital research
- Investor (buy-side or sell-side research)
- Medical device or technology
- Other products or services
PolyPid (NASDAQ: PYPD) a late-stage biopharma company with an asset at the end of phase 3 (topline data expected Q2 2025), aiming to improve surgical outcomes by delivering locally administered, controlled, prolonged-release therapeutics for a period of several day to months.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}